SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: Together, our results illustrated that SIAIS562055 and BCR–ABL inhibitors had synergistic antitumor effects on CML cells, which was associated with the upregulation of SLC22A4 caused by SIAIS562055.